InsiderTrades.com logo
Jim Cramer’s “The Biggest Drug Ever”
From Behind the Markets   |   Ad
This firm's breakthrough has drawn investments from the biggest names in Big Pharma - With companies like Biogen, Sanofi, and Genentech pouring over $1 billion into it.
Unlock the details of this groundbreaking opportunity here...

AUSC Insider Trading

Insider Ownership Percentage: 4.75%
Insider Buying (Last 12 Months): GBX 0
Insider Selling (Last 12 Months): GBX 0

abrdn UK Smaller Companies Growth Insider Trading History Chart

This chart shows the insider buying and selling history at abrdn UK Smaller Companies Growth by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

abrdn UK Smaller Companies Growth Share Price & Price History

Current Price: GBX 460
Price Change: ▲ Price Increase of +2 (0.44%)
As of 04/25/2024 01:00 AM ET

This chart shows the closing price history over time for AUSC up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Jim Cramer’s “The Biggest Drug Ever”
From Behind the Markets   |   Ad
This firm's breakthrough has drawn investments from the biggest names in Big Pharma - With companies like Biogen, Sanofi, and Genentech pouring over $1 billion into it.
Unlock the details of this groundbreaking opportunity here...

abrdn UK Smaller Companies Growth Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/22/2023Liz AireyInsiderSell40,000GBX 424£169,600
1/4/2023Tim ScholefieldInsiderBuy1,136GBX 463£5,259.68
9/16/2022Tim ScholefieldInsiderBuy1,100GBX 445£4,895
See Full Table
Jim Cramer’s “The Biggest Drug Ever”
From Behind the Markets   |   Ad
This firm's breakthrough has drawn investments from the biggest names in Big Pharma - With companies like Biogen, Sanofi, and Genentech pouring over $1 billion into it.
Unlock the details of this groundbreaking opportunity here...

SEC Filings (Institutional Ownership Changes) for abrdn UK Smaller Companies Growth (LON:AUSC)

57.98% of abrdn UK Smaller Companies Growth stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

abrdn UK Smaller Companies Growth Trust plc is a closed-ended equity mutual fund launched by Standard Life Investments Limited. The fund is managed by Standard Life Investments (Corporate Funds) Limited. It invests in the public equity markets of the United Kingdom. The fund seeks to invest in stocks of companies operating across diversified sectors. It primarily invests in stocks of mid and small-cap companies. The fund benchmarks the performance of its portfolio against the Numis Smaller Companies Index (excluding Investment Companies). It is actively managed. The fund was formerly known as Standard Life UK Smaller Companies Trust plc. abrdn UK Smaller Companies Growth Trust plc was formed on July 9, 1993 and is domiciled in the United Kingdom.
Read More on abrdn UK Smaller Companies Growth

Today's Range

Now: GBX 460
Low: 455.23
High: 463.50

50 Day Range

MA: GBX 446.51
Low: 437.50
High: 462

52 Week Range

Now: GBX 460
Low: 366
High: 465

Volume

140,880 shs

Average Volume

221,657 shs

Market Capitalization

£360.78 million

P/E Ratio

N/A

Dividend Yield

2.49%

Beta

1.01

Who are the company insiders with the largest holdings of abrdn UK Smaller Companies Growth?

abrdn UK Smaller Companies Growth's top insider shareholders include:
  1. Liz Airey (Insider)
  2. Tim Scholefield (Insider)
Learn More about top insider investors at abrdn UK Smaller Companies Growth.
Jim Cramer’s “The Biggest Drug Ever”
From Behind the Markets   |   Ad
This firm's breakthrough has drawn investments from the biggest names in Big Pharma - With companies like Biogen, Sanofi, and Genentech pouring over $1 billion into it.
Unlock the details of this groundbreaking opportunity here...